Evidence map›Paper›PMID 26836925›Full record

ReviewChest2016

Metabolic Syndrome and the Lung.

Cynthia W Baffi, Lisa Wood, Daniel Winnica, Patrick J Strollo, Mark T Gladwin, Loretta G Que, Fernando Holguin

Abstract readReview
In one paragraph

Review in Chest, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Hyperglycemia, receptor for advanced glycation end products, and small airways dysfunction in asthma.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Asthma Phenotypes and Biomarkers.Respiratory care · 2025
    Review
  18. Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cynthia W BaffiDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Lisa WoodHunter Medical Research Institute and University of Newcastle, NSW, Australia.
Daniel WinnicaDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Patrick J StrolloDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Mark T GladwinDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Loretta G QueDuke University Medical Center, Durham, NC.
Fernando HolguinDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA. Electronic address: holguinf@upmc.edu.

Funding

Redox-Derived Pulmonary Anti-Inflammatory MediatorsR01HL064937 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FREEMAN, BRUCE ALAN · 2000 to 2015
$5.6M
Anti-Inflammatory Lipid Mediators in AsthmaR01HL132550 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FREEMAN, BRUCE ALAN, HOLGUIN, FERNANDO · 2016 to 2019
$2.9M
NHLBI NIH HHS R01 HL064937NHLBI NIH HHS R01 HL132550
6 · The paper itself

Abstract

A link between metabolic syndrome (MetS) and lung diseases has been observed in several cross-sectional and longitudinal studies. This syndrome has been identified as an independent risk factor for worsening respiratory symptoms, greater lung function impairment, pulmonary hypertension, and asthma. This review will discuss several potential mechanisms to explain these associations, including dietary factors and the effect of adiposity and fat-induced inflammation on the lungs, and the role of other comorbidities that frequently coexist with MetS, such as OSA and obesity. In contrast to the well-known association between asthma and obesity, the recognition that MetS affects the lung is relatively new. Although some controversy remains as to whether MetS is a unique disease entity, its individual components have independently been associated with changes in pulmonary function or lung disease. There is, however, uncertainty as to the relative contribution that each metabolic factor has in adversely affecting the respiratory system; also, it is unclear how much of the MetS-related lung effects occur independently of obesity. In spite of these epidemiological limitations, the proposed mechanistic pathways strongly suggest that this association is likely to be causal. Given the wide prevalence of MetS in the general population, it is imperative that we continue to further understand how this metabolic disorder impacts the lung and how to prevent its complications.

Indexed as

Lung DiseasesComorbidityHumansMetabolic SyndromePrevalencePreventive MedicineRespiratory Function TestsRisk FactorsasthmaCOPDmetabolic syndromeobesityobstructive sleep apneapulmonary hypertension

Identifiers

PMID26836925
PMCPMC4944780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.